Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to boost cervical cancer treatment

NCT ID NCT07400536

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding the immunotherapy drug cadonilimab to standard chemotherapy and radiation can improve outcomes for people with locally advanced cervical cancer. About 378 participants will be randomly assigned to receive either the new combination or standard treatment alone. The main goal is to see if the new approach delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cadonilimab (an immunotherapy drug) combined with chemotherapy and radiation
What this could lead to
If successful, this could offer a more effective treatment option for locally advanced cervical cancer, potentially improving survival and reducing recurrence.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The added immunotherapy may cause more side effects, and the benefit over standard treatment is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED CERVICAL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.